Skip to main content

eftilagimod alfa

eftilagimod alfa: 2 clinical trials tracked.

eftilagimod alfa evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about eftilagimod alfa, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Breast Cancer

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

Eftilagimod Alpha in Combination With Neoadjuvant Chemotherapy in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

NCT07102940Registry updated 2026-06-11·Phase 2
Not yet recruiting

Primary endpoint: To determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment

Interventionalopen50 targetStarted 2026-09Completion 2028-08George Washington University

TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.

NCT06726265Registry updated 2026-03-18·Phase 3
Active, not recruiting

Primary endpoint: Determination of Overall survival (OS)

InterventionalRandomizedquadruple756 targetStarted 2025-03Completion 2029-0950 sites · Argentina, Australia, Austria, Belgium…Immutep S.A.S.